The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
The oxazolidinones: past, present, and future
Abstract
The success of linezolid stimulated significant efforts to discover new agents in the oxazolidinone class. Over a dozen oxazolidinones have reached the clinic, but many were discontinued due to lack of differentiated potency, inadequate pharmacokinetics, and safety risks that included myelosuppression. Four oxazolidinones are currently undergoing clinical evaluation. The Trius Therapeutics compound tedizolid phosphate (formerly known as torezolid phosphate, TR‐701, DA‐7218), the most advanced, is in phase 3 clinical trials for acute bacterial skin and skin structure infections. Rib‐X completed two phase 2 studies for radezolid (Rx‐01_667, RX‐1741) in uncomplicated skin and skin structure infections and community‐acquired pneumonia. Pfizer and AstraZeneca have each identified antitubercular compounds that have completed phase 1 studies: sutezolid (PNU‐100480, PF‐02341272) and AZD5847 (AZD2563), respectively. The oxazolidinones share a relatively low frequency of resistance largely due to the requirement of mutations in 23S ribosomal RNA genes. However, maintaining potency against strains carrying the mobile cfr gene poses a challenge for the oxazolidinone class, as well as other 50S ribosome inhibitors that target the peptidyl transferase center.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
rrndb: the Ribosomal RNA Operon Copy Number Database
Klappenbach, J. A. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.181 · Cited by 1,081
Schlünzen, F., Zarivach, R., Harms, J., Bashan, A., Tocilj, A., Albrecht, R., Yonath, A., & Franceschi, F. (2001) · Nature · doi:10.1038/35101544 · Cited by 1,059
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Long, K. S., Poehlsgaard, J., Kehrenberg, C., Schwarz, S., & Vester, B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00131-06 · Cited by 708
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9509556 · Cited by 582
Self-citationOxazolidinone Structure–Activity Relationships Leading to Linezolid
Barbachyn, M. R., & Ford, C. W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200528 · Cited by 553
Self-citationInfections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Self-citationHematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Tu, D., Blaha, G., Moore, P. B., & Steitz, T. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.005 · Cited by 433
Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases · doi:10.1086/345744 · Cited by 428
Kehrenberg, C., & Schwarz, S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1156-1163.2006 · Cited by 398
Schwarz, S., Werckenthin, C., & Kehrenberg, C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2530-2533.2000 · Cited by 341
Toh, S., Xiong, L., Arias, C. A., Villegas, M. V., Lolans, K., Quinn, J., & Mankin, A. S. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05744.x · Cited by 338
Kehrenberg, C., Schwarz, S., Jacobsen, L., Hansen, L. H., & Vester, B. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04754.x · Cited by 333
Wilson, D. N., Schluenzen, F., Harms, J. M., Starosta, A. L., Connell, S. R., & Fucini, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804276105 · Cited by 318
Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit
Ippolito, J. A., Kanyo, Z. F., Wang, D., Franceschi, F. J., Moore, P. B., Steitz, T. A., & Duffy, E. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800379d · Cited by 303
Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R., & Noskin, G. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2154-2156.2001 · Cited by 302
Linezolid resistance in clinical isolates of Staphylococcus aureus
Wilson, P. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg104 · Cited by 289
The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human Mitochondria
Leach, K. L., Swaney, S. M., Colca, J. R., McDonald, W. G., Blinn, J. R., Thomasco, L. M., Gadwood, R. C., Shinabarger, D., Xiong, L., & Mankin, A. S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.04.005 · Cited by 276
Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones
McKee, E. E., Ferguson, M., Bentley, A. T., & Marks, T. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-05 · Cited by 270
Gene Dosage and Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis
Marshall, S. H., Donskey, C. J., Hutton-Thomas, R., Salata, R. A., & Rice, L. B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3334-3336.2002 · Cited by 263
Meka, V. G., Pillai, S. K., Sakoulas, G., Wennersten, C., Venkataraman, L., DeGirolami, P. C., Eliopoulos, G. M., Moellering, Jr., & Gold, H. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/421471 · Cited by 247
Peripheral neuropathy associated with prolonged use of linezolid
Bressler, A. M., Zimmer, S. M., Gilmore, J. L., & Somani, J. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01109-0 · Cited by 246
Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model
Cynamon, M. H., Klemens, S. P., Sharpe, C. A., & Chase, S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1189 · Cited by 243
Mendes, R. E., Deshpande, L. M., Castanheira, M., DiPersio, J., Saubolle, M. A., & Jones, R. N. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00231-08 · Cited by 226
Gao, W., Chua, K., Davies, J. K., Newton, H. J., Seemann, T., Harrison, P. F., Holmes, N. E., Rhee, H.-W., Hong, J.-I., Hartland, E. L., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000944 · Cited by 218
Mechanism of action of the oxazolidinone antibacterial agents
Shinabarger, D. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.8.1195 · Cited by 211
Locke, J. B., Hilgers, M., & Shaw, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00871-09 · Cited by 205
Self-citationSafety and tolerability of linezolid
French, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg253 · Cited by 203
Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data
Lawrence, K. R., Adra, M., & Gillman, P. K. (2006) · Clinical Infectious Diseases · doi:10.1086/503839 · Cited by 200
Brickner, S. J., Barbachyn, M. R., Hutchinson, D. K., & Manninen, P. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800038g · Cited by 196
Self-citationDavidovich, C., Bashan, A., Auerbach-Nevo, T., Yaggie, R. D., Gontarek, R. R., & Yonath, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700041104 · Cited by 196
Linezolid, the first oxazolidinone antibacterial agent
Leach, K. L., Brickner, S. J., Noe, M. C., & Miller, P. F. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05962.x · Cited by 195
Shaw, K. J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C. M., Shinabarger, D., & Zurenko, G. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00859-08 · Cited by 181
Self-citationRubinstein, E., Isturiz, R., Standiford, H. C., Smith, L. G., Oliphant, T. H., Cammarata, S., Hafkin, B., Le, V., & Remington, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1824-1831.2003 · Cited by 177
Harms, J. M., Schlünzen, F., Fucini, P., Bartels, H., & Yonath, A. (2004) · BMC Biology · doi:10.1186/1741-7007-2-4 · Cited by 171
RlmN and Cfr are Radical SAM Enzymes Involved in Methylation of Ribosomal RNA
Feng, Y. F., LaMarre, J. M., Röhrich, R. C., Wiesner, J., Jomaa, H., Mankin, A. S., & Fujimori, D. G. (2010) · Journal of the American Chemical Society · doi:10.1021/ja910850y · Cited by 170
Besier, S. M., Ludwig, A., Zander, J., Brade, V., & Wichelhaus, T. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01098-07 · Cited by 169
The methyltransferase YfgB/RlmN is responsible for modification of adenosine 2503 in 23S rRNA
Toh, S., Xiong, L., Bae, T., & Mankin, A. S. (2007) · RNA · doi:10.1261/rna.814408 · Cited by 168
Wolter, N., Smith, A. M., Farrell, D. J., Schaffner, W., Moore, M. R., Whitney, C. G., Jorgensen, J. H., & Klugman, K. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3554-3557.2005 · Cited by 165
Locke, J. B., Finn, J., Hilgers, M. T., Morales, G., Rahawi, S., Kedar, G. C., Picazo, J. J., Im, W., Shaw, K. J., & Stein, J. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00663-10 · Cited by 164
Self-citationGiessing, A. M. B., Jensen, S. S., Rasmussen, A., Hansen, L. H., Gondela, A., Long, K. S., Vester, B., & Kirpekar, F. (2009) · RNA · doi:10.1261/rna.1371409 · Cited by 162
Mendes, R. E., Deshpande, L. M., Farrell, D. J., Spanu, T., Fadda, G., & Jones, R. N. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq331 · Cited by 155
Locke, J. B., Hilgers, M. T., & Shaw, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01032-09 · Cited by 145
Self-citationDiscovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent
Im, W. B., Choi, S. H., Park, J., Choi, S. H., Finn, J., & Yoon, S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.014 · Cited by 139
Reversible Inhibition of Mitochondrial Protein Synthesis during Linezolid-Related Hyperlactatemia
Garrabou, G., Soriano, A., López, S., Guallar, J. P., Giralt, M., Villarroya, F., Martínez, J. A. B., Casademont, J., Cardellach, F., Mensa, J., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01190-06 · Cited by 126
Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis
Williams, K. N., Brickner, S. J., Stover, C. K., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0611oc · Cited by 125
Gales, A. C., Sader, H. S., ANDRADE, S., Lutz, L., MACHADO, A., & Barth, A. L. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.11.008 · Cited by 124
Smith, L. K., & Mankin, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01583-07 · Cited by 122
Schaadt, R. D., Sweeney, D., Shinabarger, D. L., & Zurenko, G. E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00228-09 · Cited by 117
Prokocimer, P., Bien, P. A., Surber, J., Mehra, P., DeAnda, C., Bulitta, J. B., & Corey, G. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00076-10 · Cited by 115
Kaatz, G. W., & Seo, S. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.799 · Cited by 112
Serotonin Syndrome and Linezolid
Wigen, C. L., & Goetz, M. B. (2002) · Clinical Infectious Diseases · doi:10.1086/340710 · Cited by 110
Florfenicol-Chloramphenicol Exporter Gene fexA Is Part of the Novel Transposon Tn 558
Kehrenberg, C., & Schwarz, Š. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.813-815.2005 · Cited by 108
Wallis, R. S., Jakubiec, W., Kumar, V., Silvia, A. M., Paige, D., Dimitrova, D., Li, X., Ladutko, L., Campbell, S. M., Friedland, G. H., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/655471 · Cited by 105
Sander, P., Belova, L., Kidan, Y. G., Pfister, P., Mankin, A. S., & Böttger, E. C. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03242.x · Cited by 102
Slatter, J. G., Adams, L. A., Bush, E. C., et al. (2002) · Xenobiotica · doi:10.1080/00498250210158249 · Cited by 101
Kehrenberg, C., Ojo, K. K., & Schwarz, Š. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh457 · Cited by 100
Sinclair, A., Arnold, C. E., & Woodford, N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3620-3622.2003 · Cited by 99
Beekmann, S. E., Gilbert, D. N., & Polgreen, P. M. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.009 · Cited by 93
Farrell, D. J., Mendes, R. E., Ross, J. E., Sader, H. S., & Jones, R. N. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01729-10 · Cited by 93
Livermore, D. M., Mushtaq, S., Warner, M., & Woodford, N. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp002 · Cited by 91
Kaminska, K. H., Purta, E., Hansen, L. H., Bujnicki, J. M., Vester, B., & Long, K. S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1142 · Cited by 91
Louie, A., Liu, W., Kulawy, R., & Drusano, G. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01565-10 · Cited by 90
Polyphyletic Emergence of Linezolid-Resistant Staphylococci in the United States
Wong, A., Reddy, S. P., Smyth, D. S., Aguero‐Rosenfeld, M. E., Sakoulas, G., & Robinson, D. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00621-09 · Cited by 85
Dai, L., Wu, C., Wang, M., Wang, Y., Wang, Y., Huang, S., Xia, L., Li, B., & Shen, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00169-10 · Cited by 85
Locke, J. B., Morales, G., Hilgers, M. T., Kedar, G. C., Rahawi, S., Picazo, J. J., Shaw, K. J., & Stein, J. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00714-10 · Cited by 83
Self-citationKelly, S., Collins, J., Maguire, M., Gowing, C., Flanagan, M., Donnelly, M., & Murphy, P. G. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn043 · Cited by 81
Rχ-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance
Skripkin, E. A., McConnell, T., DeVito, J., Lawrence, L. E., Ippolito, J. A., Duffy, E. M., Sutcliffe, J. A., & Franceschi, F. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-07 · Cited by 80
Farrell, D. J., Morrissey, I., Bakker, S., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.3169-3171.2004 · Cited by 80
Serotonin Toxicity Associated with Concomitant Use of Linezolid
Bergeron, L. E., Boulé, M., & Perreault, S. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e523 · Cited by 79
Mendes, R. E., Deshpande, L. M., Rodríguez-Noriega, E., Ross, J. E., Jones, R. N., & Morfín‐Otero, R. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00880-10 · Cited by 78
In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens
Lawrence, L. E., Danese, P. N., DeVito, J. A., Franceschi, F. J., & Sutcliffe, J. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01383-07 · Cited by 75
Komine, T., Kojima, A., Asahina, Y., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800800c · Cited by 74
The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics
Auerbach, T., Mermershtain, I., Davidovich, C., Bashan, A., Belousoff, M. J., Wekselman, I., Zimmerman, E., Xiong, L., Klepacki, D., Arakawa, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914100107 · Cited by 73
Detection of the staphylococcal multiresistance gene cfr in Proteus vulgaris of food animal origin
Wang, Y., Wang, Y., Wu, C., Schwarz, Š., Shen, Z., Zhang, W., Zhang, Q., & Shen, J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr322 · Cited by 73
Low Fitness Cost of the Multidrug Resistance Gene cfr
LaMarre, J. M., Locke, J. B., Shaw, K. J., & Mankin, A. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00153-11 · Cited by 71
Self-citationMechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound
Daly, J. S., Eliopoulos, G. M., Willey, S., & Moellering, R. C. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.9.1341 · Cited by 71
Antal, E. J., Hendershot, P. E., Batts, D. H., Sheu, W.-P., Hopkins, N. K., & Donaldson, K. M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010294 · Cited by 69
Long, K. S., Munck, C., Andersen, T. M. B., Schaub, M. A., Hobbie, S. N., Böttger, E. C., & Vester, B. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00644-10 · Cited by 69
Visualization of ribosomal RNA operon copy number distribution
Rastogi, R., Wu, M., Dasgupta, I., & Fox, G. E. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-208 · Cited by 69
Lemaire, S., Françoise Van Bambeke, A., Appelbaum, P. C., & Tulkens, P. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp267 · Cited by 60
Anti-infectives : recent advances in chemistry and structure-activity relationships
Bentley, P. H., & O’Hanlon, P. J. (1997) · Cited by 57
LaMarre, J. M., Howden, B. P., & Mankin, A. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00183-11 · Cited by 56
Sorlózano, A., Fernández, J. G., Martinez, T., Yuste, M. E., Pérez-López, J. A., Vindel, A., Guillen, J., & Boquete, T. (2009) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0823-4 · Cited by 51
Biedenbach, D. J., Farrell, D. J., Mendes, R. E., Ross, J. E., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.09.018 · Cited by 46
Tsakris, A., Pillai, S. K., Gold, H. S., Thauvin-Eliopoulos, C., Venkataraman, L., Wennersten, C. B., Moellering, R. C., & Eliopoulos, G. M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm246 · Cited by 43
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens
Jones, R., Moet, G., Sader, H. S., Mendes, R. E., & Castanheira, M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp021 · Cited by 39
Linezolid and Serotonin Toxicity
Gillman, P. K. (2003) · Clinical Infectious Diseases · doi:10.1086/378895 · Cited by 31
Bae, S. K., Chung, W., Kim, E. J., Rhee, J. K., Kwon, J. W., Kim, W. B., & Lee, M. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.659-662.2004 · Cited by 24
Picazo, J. J., Betriú, C., Culebras, E., Rodríguez-Avial, I., Gómez, M., & López, F. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.03.020 · Cited by 12
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Targeting Antibiotic Resistance
Chellat, M. F., Raguž, L., & Riedl, R. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201506818 · Cited by 487
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
New antibiotics for bad bugs: where are we?
Bassetti, M., Merelli, M., Temperoni, C., & Astilean, A. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-22 · Cited by 403
Metadata
- Authors
- Shaw, K. J., & Barbachyn, M. R.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2011-12
- Volume
- 1241
- Issue
- 1
- Pages
- 48-70
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1529101966
- Cited by
- 259
- References
- 92
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.